NURS 4210: Population Health
Screening Guidelines Exam -Questions
And Answers With Rationales/Graded
A+/2026 Update/100% Correct /Instant
Download
Section I: Breast Cancer Screening (Questions 1–12)
1. According to the 2026 USPSTF final recommendation, screening
mammography for average-risk women should begin at what age?
a) 40 years
b) 50 years
c) 45 years
d) 55 years
Rationale: The USPSTF 2026 reaffirms biennial screening starting at age 50 for
average-risk women, though shared decision-making is recommended for ages 40–
49.
2. What is the recommended screening interval for mammography in women
aged 50–74 years (USPSTF 2026)?
a) Annually
b) Every 2 years
c) Every 3 years
d) Once every 5 years
Rationale: Biennial screening balances benefits (reduced mortality) with harms
(false positives, overdiagnosis).
3. At what age should routine screening mammography stop per USPSTF
2026?
a) 65 years
b) 74 years
,c) 80 years
d) Never stop
Rationale: Insufficient evidence to recommend for or against screening after age
74 in average-risk women.
4. Which organization recommends annual mammography starting at age 40?
a) USPSTF
b) American College of Radiology (ACR)
c) WHO
d) AAFP
Rationale: The ACR and American Cancer Society (ACS) differ from USPSTF,
recommending annual screening from age 40.
5. A 52-year-old woman with dense breasts asks about supplemental
screening. What does USPSTF 2026 state?
a) Recommend whole-breast ultrasound annually
b) Insufficient evidence to recommend for or against supplemental imaging
c) Recommend MRI annually
d) Recommend against any supplemental screening
Rationale: USPSTF cites lack of evidence that supplemental screening reduces
mortality in dense breasts.
6. Which of the following is a harm of breast cancer screening?
a) Reduced breast cancer mortality
b) Overdiagnosis
c) Increased detection of early-stage cancers
d) Patient reassurance
Rationale: Overdiagnosis (detecting cancer that would never cause symptoms) is a
well-documented harm.
7. For women with a known BRCA1 mutation, screening should begin at:
a) Same as general population
b) Age 30 with annual MRI and mammography
c) Age 40 with MRI only
d) Age 25 with mammography only
Rationale: High-risk women (BRCA carriers) need earlier, more intensive
screening per NCCN 2026.
, 8. Clinical breast examination (CBE) is recommended by USPSTF 2026 as:
a) Annually for all women over 40
b) No recommendation (insufficient evidence)
c) Strongly recommended
d) Only for women under 30
Rationale: USPSTF found insufficient evidence to assess balance of
benefits/harms of CBE.
9. A 68-year-old woman with a life expectancy of 5 years due to COPD asks
about continuing mammograms. Best action:
a) Continue biennial screening
b) Discuss stopping screening due to limited life expectancy
c) Switch to annual screening
d) Order breast MRI
Rationale: Screening benefits take 7–10 years to manifest; not indicated if life
expectancy <10 years.
10. Which racial/ethnic group has the highest breast cancer mortality rate in
the U.S. as of 2026?
a) White women
b) Asian women
c) Hispanic women
d) Black women
Rationale: Black women have 40% higher breast cancer mortality despite similar
incidence, partly due to aggressive subtypes and access issues.
11. What is the recommended screening modality for a pregnant woman with
a palpable breast lump?
a) Mammography with abdominal shield
b) Ultrasound
c) MRI with contrast
d) Delay until postpartum
Rationale: Ultrasound is safe and effective for evaluating palpable lumps in
pregnancy.
12. Tomosynthesis (3D mammography) compared to digital mammography:
a) Higher radiation dose without benefit
Screening Guidelines Exam -Questions
And Answers With Rationales/Graded
A+/2026 Update/100% Correct /Instant
Download
Section I: Breast Cancer Screening (Questions 1–12)
1. According to the 2026 USPSTF final recommendation, screening
mammography for average-risk women should begin at what age?
a) 40 years
b) 50 years
c) 45 years
d) 55 years
Rationale: The USPSTF 2026 reaffirms biennial screening starting at age 50 for
average-risk women, though shared decision-making is recommended for ages 40–
49.
2. What is the recommended screening interval for mammography in women
aged 50–74 years (USPSTF 2026)?
a) Annually
b) Every 2 years
c) Every 3 years
d) Once every 5 years
Rationale: Biennial screening balances benefits (reduced mortality) with harms
(false positives, overdiagnosis).
3. At what age should routine screening mammography stop per USPSTF
2026?
a) 65 years
b) 74 years
,c) 80 years
d) Never stop
Rationale: Insufficient evidence to recommend for or against screening after age
74 in average-risk women.
4. Which organization recommends annual mammography starting at age 40?
a) USPSTF
b) American College of Radiology (ACR)
c) WHO
d) AAFP
Rationale: The ACR and American Cancer Society (ACS) differ from USPSTF,
recommending annual screening from age 40.
5. A 52-year-old woman with dense breasts asks about supplemental
screening. What does USPSTF 2026 state?
a) Recommend whole-breast ultrasound annually
b) Insufficient evidence to recommend for or against supplemental imaging
c) Recommend MRI annually
d) Recommend against any supplemental screening
Rationale: USPSTF cites lack of evidence that supplemental screening reduces
mortality in dense breasts.
6. Which of the following is a harm of breast cancer screening?
a) Reduced breast cancer mortality
b) Overdiagnosis
c) Increased detection of early-stage cancers
d) Patient reassurance
Rationale: Overdiagnosis (detecting cancer that would never cause symptoms) is a
well-documented harm.
7. For women with a known BRCA1 mutation, screening should begin at:
a) Same as general population
b) Age 30 with annual MRI and mammography
c) Age 40 with MRI only
d) Age 25 with mammography only
Rationale: High-risk women (BRCA carriers) need earlier, more intensive
screening per NCCN 2026.
, 8. Clinical breast examination (CBE) is recommended by USPSTF 2026 as:
a) Annually for all women over 40
b) No recommendation (insufficient evidence)
c) Strongly recommended
d) Only for women under 30
Rationale: USPSTF found insufficient evidence to assess balance of
benefits/harms of CBE.
9. A 68-year-old woman with a life expectancy of 5 years due to COPD asks
about continuing mammograms. Best action:
a) Continue biennial screening
b) Discuss stopping screening due to limited life expectancy
c) Switch to annual screening
d) Order breast MRI
Rationale: Screening benefits take 7–10 years to manifest; not indicated if life
expectancy <10 years.
10. Which racial/ethnic group has the highest breast cancer mortality rate in
the U.S. as of 2026?
a) White women
b) Asian women
c) Hispanic women
d) Black women
Rationale: Black women have 40% higher breast cancer mortality despite similar
incidence, partly due to aggressive subtypes and access issues.
11. What is the recommended screening modality for a pregnant woman with
a palpable breast lump?
a) Mammography with abdominal shield
b) Ultrasound
c) MRI with contrast
d) Delay until postpartum
Rationale: Ultrasound is safe and effective for evaluating palpable lumps in
pregnancy.
12. Tomosynthesis (3D mammography) compared to digital mammography:
a) Higher radiation dose without benefit
